Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Autor: Krens LL; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600 NL, 2300 RC, Leiden, The Netherlands, l.l.krens@lumc.nl., Baas JM, Verboom MC, Paintaud G, Desvignes C, Guchelaar HJ, Gelderblom H
Jazyk: angličtina
Zdroj: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2014 Jun; Vol. 73 (6), pp. 1303-6. Date of Electronic Publication: 2014 Apr 06.
DOI: 10.1007/s00280-014-2462-4
Abstrakt: Introduction: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab.
Material and Methods: Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t(1/2)), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function.
Results: The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function.
Conclusion: This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.
Databáze: MEDLINE
Externí odkaz: